USPTO 2015–2025 USPTO PatentsView US Corporation

Cognos Therapeutics, Inc.

USPTO PatentsView assignee record - 7 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

RSS updates for this company

The verdict

According to USPTO PatentsView, Cognos ranks #34,798 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 6 technology areas.

#34,798
of 49,997 US assignees by volume
Top 29%
by Innovation Score (43.1/100)
12.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R34798 · US Corporation #34,798 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 7 grants
  • MID-PACK #34,798/49,997
  • PHOTO-FINISH CMC Biologics A/S
  • CPC-NARROW A61M · 6 areas
  • INNOV-PAR 43.1/100
  • CLAIMS-RICH 12.1 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2020–2025 · 6y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: CMC Biologics A/S (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Cognos

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Cognos's Innovation Score is 43.1/100 (top 29% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Cognos's grants concentrate

Cognos Therapeutics, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2020. By volume, Cognos sits between CMC Biologics A/S and Color Health, Inc..

Cognos's three-year grant acceleration

Cognos Therapeutics, Inc. shows 5 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Cognos's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Cognos holds 7 patents at rank #34,704, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Cognos

By rank, the assignees closest to #34,704 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Cognos's primary technology class.

Cognos's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 29% higher than 71% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 2020202220242025 1
USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Cognos Therapeutics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 1 14.3%
2022 1 14.3%
2024 4 57.1%
2025partial year 1 14.3%

Where it ranks

Overall rank by patents

#34,798

of 49,997 tracked assignees

Innovation Score

43.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Cognos Therapeutics, Inc.'s patent record in context - here's where to go next.

  • Cognos Therapeutics, Inc.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 100% of its portfolio - see every assignee active in that class. Explore A61M
  • Ranked #34,798 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Cognos Therapeutics, Inc. against CMC Biologics A/S, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 43.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.